SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure after reports that CEO Jensen Huang had a relationship with a businesswoman suspected by U.S. intelligence of being a Chinese spy, prompting an independent board investigation. Traders are divided between seeing potential governance, national-security and leadership risks and viewing the controversy as overblown with little impact on NVIDIAs business.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios quarterly report missed revenue expectations, with traders focused on weaker-than-expected Anktiva sales and sequentially declining product revenue; some worry about execution and future funding, while bullish investors argue that the results predate recent label expansions and international launches. The debate is also shaped by the positive QUILT-2.005 trial update and anticipation of full data and a planned FDA filing, which bulls see as potential support for broader bladder-cancer use.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Q3 results beat expectations and management raised its full-year revenue outlook on continued BRIUMVI growth, prompting mostly bullish reactions. Traders are also focused on the upcoming subcutaneous BRIUMVI Phase 3 readout, though some caution that strong results may already be priced in.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Attention centers on Trade Desks quarterly earnings and guidance after a prolonged share-price slump, with bearish traders warning of continued weak growth and execution while bulls hope for a turnaround, citing strength at ad-tech peers and co-founder Dave Pickles return to a technology leadership role. Heavy short-interest talk adds speculation about a squeeze, but the direction of any earnings reaction is widely disputed.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes submitted sonelokimab BLA for hidradenitis suppurativa and the pending FDA decision on whether to accept itand what review timeline to assignare the main focus. Bulls point to the drugs clinical results and pipeline, while skeptics highlight regulatory uncertainty, competition, and the cost and dilution risk of launching without a partner.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs agreement to acquire substantially all of Heron Therapeutics assets, adding four commercial products, is drawing attention. Some traders view the deal as a way to broaden revenue and capture synergies, while others worry about the cash-and-stock consideration and potential pressure on CRMD shares.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,200,877.25744775. The last known price of Ethereum is 2,141.49627095 USD and is down -4.09 over the last 24 hours. It is currently trading on 14297 active market(s) with $9,084,277,576.13 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp selloff and broader crypto weakness, with traders citing leveraged-long liquidations and debating whether further downside or a recovery is ahead. Bearish calls about broken support and weak price action contrast with dip-buying and bottom-calling; proposed links to tech-market moves and macro concerns remain speculation.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellations strong quarterly results and raised full-year outlook are driving attention, reinforcing optimism about its earnings visibility and exposure to AI-related electricity demand. Traders are broadly positive but some question why the stocks gain is modest, while others remain cautious about heavy investment and whether future data-center demand will translate into returns.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Heluss expected Q4 Phase 3 APPROACH topline readout for HLP003, its adjunctive major-depression candidate; traders debate whether the Phase 2 signal and add-on trial design can translate into a successful pivotal result. Optimism around the catalyst is balanced by concerns about binary trial risk, potential dilution, and competition following reports of a Usona psilocybin NDA filing.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep slide alongside a broader crypto selloff dominates discussion, with traders also pointing to political uncertainty and doubts about crypto legislation such as the Clarity Act. Sentiment is split between calls to sell as XRP approaches the psychologically important $1 level and dip-buyers arguing the decline is an accumulation opportunity.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
